<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">marinedrugs</journal-id>
      <journal-title>Marine Drugs</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Mar. Drugs</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Marine Drugs</abbrev-journal-title>
      <issn pub-type="epub">1660-3397</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/md10040881</article-id>
      <article-id pub-id-type="publisher-id">marinedrugs-10-00881</article-id>
      <article-categories>
        <subj-group>
          <subject>Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>First Total Synthesis of a Naturally Occurring Iodinated 5′-Deoxyxylofuranosyl Marine Nucleoside</article-title>
      </title-group>
      
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>Jianyun</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dou</surname>
            <given-names>Yanhui</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ding</surname>
            <given-names>Haixin</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Ruchun</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>Qi</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Xiao</surname>
            <given-names>Qiang</given-names>
          </name>
          <xref rid="c1-marinedrugs-10-00881" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-marinedrugs-10-00881">Jiangxi Key Laboratory of Organic Chemistry, Jiangxi Science Technology Normal University, Nanchang 330013, China; Email: <email>sjy089@163.com</email> (J.S.); <email>tdlybh521@163.com</email> (Y.D.); <email>dinghaixin@yahoo.cn</email> (H.D.); <email>ouyangruchun@yahoo.cn</email> (R.Y.); <email>dr.purevision@gmail.com</email> (Q.S.)</aff>
      <author-notes>
        <corresp id="c1-marinedrugs-10-00881"><label>*</label> Author  to whom correspondence should be addressed; Email: <email>xiaoqiang@tsinghua.org.cn</email>; Tel./Fax: +86-791-86422903.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>04</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>04</month>
        <year>2012</year>
      </pub-date>
      <volume>10</volume>
      <issue>4</issue>
      <fpage>881</fpage>
      <lpage>889</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>01</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>16</day>
          <month>03</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>03</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>©  2012 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>4-Amino-7-(5′-deoxy-β-<sc>D</sc>-xylofuranosyl)-5-iodo-pyrrolo[2,3-<italic>d</italic>]pyrimidine <bold>1</bold>, an unusual naturally occurring marine nucleoside isolated from an ascidan, <italic>Diplosoma</italic> sp., was synthesized from <sc>D</sc>-xylose in seven steps with 28% overall yield on 10 g scale. The key step was Vorbrüggen glycosylation of 5-iodo-pyrrolo[2,3-<italic>d</italic>]pyrimidine with 5-deoxy-1,2-<italic>O</italic>-diacetyl-3-<italic>O</italic>-benzoyl-<sc>D</sc>-xylofuranose. Its absolute configuration was confirmed.</p>
      </abstract>
      <kwd-group>
        <kwd>Vorbrüggen glycosylation</kwd>
        <kwd>total synthesis</kwd>
        <kwd>pyrrolo[2,3-<italic>d</italic>]pyrimidine</kwd>
        <kwd>marine nucleoside</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>1. Introduction</title>
      <p>Naturally occurring deazapurine nucleosides, such as tubercidin [<xref ref-type="bibr" rid="B1-marinedrugs-10-00881">1</xref>], toyocamycin [<xref ref-type="bibr" rid="B2-marinedrugs-10-00881">2</xref>], sangivamycin [<xref ref-type="bibr" rid="B3-marinedrugs-10-00881">3</xref>], cadeguomycin [<xref ref-type="bibr" rid="B4-marinedrugs-10-00881">4</xref>] and recently isolated marine nucleoside 5-iodo-5′-deoxytubercidin, mycalesine <bold>A</bold> and <bold>B</bold> [<xref ref-type="bibr" rid="B5-marinedrugs-10-00881">5</xref>], showed significant biological activities. Structurally related pyrrolo[2,3-<italic>d</italic>]pyrimidine nucleosides have triggered the continued interest of medicinal chemists in the past decades [<xref ref-type="bibr" rid="B6-marinedrugs-10-00881">6</xref>,<xref ref-type="bibr" rid="B7-marinedrugs-10-00881">7</xref>,<xref ref-type="bibr" rid="B8-marinedrugs-10-00881">8</xref>].</p>
      <p>Although many uncommon nucleosides have been isolated from terrestrial and marine organisms [<xref ref-type="bibr" rid="B5-marinedrugs-10-00881">5</xref>,<xref ref-type="bibr" rid="B9-marinedrugs-10-00881">9</xref>,<xref ref-type="bibr" rid="B10-marinedrugs-10-00881">10</xref>], nucleosides containing <sc>D</sc>-xylofuranose are rare in nature [<xref ref-type="bibr" rid="B11-marinedrugs-10-00881">11</xref>]. In 2008, 4-amino-7-(5′-deoxy-β-<sc>D</sc>-xylofuranosyl)-5-iodo-pyrrolo[2,3-<italic>d</italic>]pyrimidine <bold>1</bold> was first isolated by Japanese scientists from an ascidan, <italic>Diplosoma</italic> sp. It was found that nucleoside <bold>1</bold> causes complete inhibition of cell division in fertilized sea urchin eggs at 1 µg/mL concentration [<xref ref-type="bibr" rid="B12-marinedrugs-10-00881">12</xref>]. This compound is a potential lead for development of new insecticides. As part of our continuing effort for synthesis of bioactive natural 7-deazapurine nucleosides, we report the first total synthesis and structure confirmation of <bold>1</bold>.</p>
    </sec>
    <sec sec-type="results">
      <title>2. Results and Discussion</title>
      <p>In nucleoside chemistry, Vorbrüggen glycosylation (Silyl-Hilbert-Johnson reaction) is one of the most efficient approaches for nucleoside synthesis. This reaction has been widely applied in academic and industrial research [<xref ref-type="bibr" rid="B13-marinedrugs-10-00881">13</xref>,<xref ref-type="bibr" rid="B14-marinedrugs-10-00881">14</xref>,<xref ref-type="bibr" rid="B15-marinedrugs-10-00881">15</xref>]. According to the proposed mechanism of Vorbrüggen glycosylation, silylated nucleobase attacks the intermediate oxonium to give desired nucleoside. Different from purine and pyrimidine nucleobases, such as adenine and thymine, pyrrolo[2,3-<italic>d</italic>]pyrimidines (7-deazapurine) were seldom used as donors in Vorbrüggen glycosylation. The reason might be possibly ascribed to the nonreactive nature of N-7 in pyrrolo[2,3-<italic>d</italic>]pyrimidines [<xref ref-type="bibr" rid="B16-marinedrugs-10-00881">16</xref>,<xref ref-type="bibr" rid="B17-marinedrugs-10-00881">17</xref>].</p>
      <p>In order to circumvent this problem, nucleobase-anion glycosylation protocol was developed for the synthesis of 7-deazapurine nucleosides and their analogues by Robins [<xref ref-type="bibr" rid="B18-marinedrugs-10-00881">18</xref>,<xref ref-type="bibr" rid="B19-marinedrugs-10-00881">19</xref>] and Seela [<xref ref-type="bibr" rid="B20-marinedrugs-10-00881">20</xref>,<xref ref-type="bibr" rid="B21-marinedrugs-10-00881">21</xref>,<xref ref-type="bibr" rid="B22-marinedrugs-10-00881">22</xref>]. In this approach, labile α-<sc>D</sc>-furanosyl chloride intermediates, such as <bold>2</bold>, must be prepared via a lengthy synthetic route with poor yield [<xref ref-type="bibr" rid="B23-marinedrugs-10-00881">23</xref>,<xref ref-type="bibr" rid="B24-marinedrugs-10-00881">24</xref>] (<xref ref-type="fig" rid="marinedrugs-10-00881-f001">Figure 1</xref>). This drawback limits its application. </p>
      <fig id="marinedrugs-10-00881-f001" position="anchor">
        <label>Figure 1</label>
        <caption>
          <p>Chemical structure of pyrrolo[2,3-<italic>d</italic>]pyrimidine nucleoside <bold>1</bold> and its retrosynthetic analysis.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="marinedrugs-10-00881-g001.tif"/>
      </fig>
      <p>From a synthetic point of view, Vorbrüggen glycosylation is one of the ideal choices for synthesis of pyrrolo[2,3-<italic>d</italic>]pyrimidine nucleosides because of commercial availability of carbohydrate acceptors. Recently, it was found that pyrrolo[2,3-<italic>d</italic>]pyrimidine nucleobases with electro-withdrawing groups (such as Cl, Br, I, <italic>etc</italic>.) at 5-position can be successfully used as donors in Vorbrüggen glycosylation for the preparation of pyrrolo[2,3-<italic>d</italic>]pyrimidine nucleosides with good yields [<xref ref-type="bibr" rid="B25-marinedrugs-10-00881">25</xref>,<xref ref-type="bibr" rid="B26-marinedrugs-10-00881">26</xref>,<xref ref-type="bibr" rid="B27-marinedrugs-10-00881">27</xref>,<xref ref-type="bibr" rid="B28-marinedrugs-10-00881">28</xref>]. However, its application in synthesis of xylofuranose pyrrolo[2,3-<italic>d</italic>]pyrimidine nucleosides has not been reported. It is important to further prove this protocol’s generality and reproducibility. We herein report a practical and efficient synthesis of <bold>1</bold> from <sc>D</sc>-xylose with application of Vorbrüggen glycosylation as the key step (<xref ref-type="scheme" rid="marinedrugs-10-00881-f002">Scheme 1</xref>).</p>
      <fig id="marinedrugs-10-00881-f002" position="anchor">
        <label>Scheme 1</label>
        <caption>
          <p>Total synthesis of pyrrolo[2,3-<italic>d</italic>]pyrimidine nucleoside <bold>1</bold>. Reagents and conditions: (<bold>a</bold>) (a1) Conc. H<sub>2</sub>SO<sub>4</sub>, acetone, 0 °C, 3 h; (a2) 5% Na<sub>2</sub>CO<sub>3</sub> aq., 30 min, 87%; (<bold>b</bold>) TsCl (1.1 eq.), THF, Et<sub>3</sub>N, 0 °C, overnight, 92%; (<bold>c</bold>) LiAlH<sub>4</sub> (0.5 eq.), THF, reflux, 6 h, 95%; (<bold>d</bold>) BzCl (1.1 eq), CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, 2 h, 98%; (<bold>e</bold>) Conc. H<sub>2</sub>SO<sub>4</sub>, Ac<sub>2</sub>O, 26 h, 78%; (<bold>f</bold>) POCl<sub>3</sub> (excess), reflux, 3 h, 98%; (<bold>g</bold>) NIS (1.01 eq.), DMF, 0 °C, 2 h, 98%; (<bold>h</bold>) <bold>4</bold> (1 eq.), BSA (1.2 eq.), TMSOTf (1 eq.), CH<sub>3</sub>CN, rt-80 °C, 12 h 56%; (<bold>i</bold>) Sat. NH<sub>3</sub> in MeOH (excess), 130 °C, 12 h, 82%.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="marinedrugs-10-00881-g002.tif"/>
      </fig>
      <p>5-Deoxy-<sc>D</sc>-xylose glycosylation acceptor <bold>3</bold> was synthesized starting with <sc>D</sc>-xylose <bold>5</bold>. Crystalline 1,2-<italic>O</italic>-isopropylidene-α-<sc>D</sc>-xylofuranose <bold>6</bold> was prepared in 87% yield by sulfuric acid-catalyzed acetalation of <sc>D</sc>-xylose, followed by partial hydrolysis with aqueous sodium carbonate added directly to the crude acetalation mixture in one pot [<xref ref-type="bibr" rid="B29-marinedrugs-10-00881">29</xref>]. Then 5-OH was selectively tosylated with <italic>p</italic>-toluenesulfonyl chloride and triethylamine in THF to afford monotosylate <bold>7</bold> in 92% yield. After refluxing with 2 equiv. of LiAlH<sub>4</sub> in anhydrous THF, the tosylate was reduced to a methyl group in excellent 95% yield to afford <bold>8</bold> [<xref ref-type="bibr" rid="B30-marinedrugs-10-00881">30</xref>]. Subsequent benzoylation of 3-OH gave compound <bold>9</bold> in almost quantitative yield. Finally, the acetonide <bold>9</bold> was transformed to <sc>D</sc>-xylose diacetate glycosylation acceptor <bold>3</bold> as a mixed isomers (α:β = 2:3) on 50 g scale [<xref ref-type="bibr" rid="B31-marinedrugs-10-00881">31</xref>].</p>
      <p>For preparation of nucleobase <bold>4</bold>, chlorination of pyrrolo[2,3-<italic>d</italic>]pyrimidin-4-ol <bold>11</bold> with phosphoryl chloride gave 4-chloro-7<italic>H</italic>-pyrrolo[2,3-<italic>d</italic>]pyrimidine <bold>12</bold> in 93% yield [<xref ref-type="bibr" rid="B32-marinedrugs-10-00881">32</xref>,<xref ref-type="bibr" rid="B33-marinedrugs-10-00881">33</xref>]. The reaction of <bold>12</bold> with 1.05 equiv. of NIS in DMF at room temperature afforded the iodinated base <bold>4</bold> in 95% yield on 100 g scale [<xref ref-type="bibr" rid="B25-marinedrugs-10-00881">25</xref>].</p>
      <p>Next, we intended to synthesize the target molecule <bold>1</bold> using Vorbrüggen glycosylation. After extensive optimization of various Lewis acids, solvents, reaction temperature, it was found that the best condition were the useof 1.2 equiv. of bis(trimethylsilyl)acetamide (BSA) as silylating reagent, 2 equiv. oftrimethylsilyl triflate (TMSOTf) as Lewis acid, freshly distilled acetonitrile as solvent, and heating at 80 °C for 12 h. Then 1 equiv. 5-iodo-7<italic>H</italic>-pyrrolo[2,3-<italic>d</italic>]pyrimidine <bold>4</bold> was first treated with 1.2 equiv. of BSA, followed by 1.2 equiv. of 5′-deoxy-1,2,3-tri-<italic>O</italic>-acetyl-β-<sc>D</sc>-xylofuranose <bold>3</bold> and 2 equiv. of TMSOTf at room temperature. The resulting mixture was heated to 80 °C for 12 h. After workup, column chromatography afforded 4-chloro-7-(5′-deoxy-β-<sc>D</sc>-xylofuranosyl)-5-iodo-pyrrolo[2,3-<italic>d</italic>]pyrimidine <bold>10</bold> in 56% yield as pure β anomer on 20 g scale. The glycosylation yield was lower than that of the corresponding 5′-deoxy-1,2,3-tri-<italic>O</italic>-acetyl-<sc>D</sc>-ribofuranose acceptor, which typically gave more than 80% yield [<xref ref-type="bibr" rid="B25-marinedrugs-10-00881">25</xref>]. It may be due to the steric hindrance of 3′-β substitute. At last, <bold>10</bold> was suspended in a saturated solution of ammonia in methanol, and the resulting solution was heated at 130 °C in an autoclave for 12 h to remove the protecting ester groups and substitute the 4-Cl by 4-NH<sub>2</sub>on the base. The target nucleoside <bold>1</bold> [<xref ref-type="bibr" rid="B12-marinedrugs-10-00881">12</xref>] was obtained in 82% yield on 10 g scale (<xref ref-type="scheme" rid="marinedrugs-10-00881-f002">Scheme 1</xref>), which is sufficient for further biological studies and structure modification.</p>
      <p>Because both <sc>D</sc> and <sc>L</sc> carbohydrate are present in marine natural products, Ueda and coworkers synthesized dibenzoates of <bold>1</bold> and 1-methyl-<italic>O</italic>-5-deoxy-β-<sc>L</sc>-xylofuranoside and compared their CD spectra to determine the absolute configuration of <bold>1</bold> [<xref ref-type="bibr" rid="B12-marinedrugs-10-00881">12</xref>]. According to their opposite cotton effect curves, the absolute configuration of <bold>1</bold> was indirectly determined to be <sc>D</sc>. In order to further confirm its precise configuration, the CD spectrum of synthesized <bold>1</bold> was determined and found identical to reported data [λ<sub>ext</sub> 242 nm (∆ε −1.9) and λ<sub>ext</sub> 210 nm (∆ε −2.6)]. Furthermore, because the starting material is <sc>D</sc>-xylose, the absolute configuration of nucleoside <bold>1</bold> is undoubtedly <sc>D</sc>. All other spectral data are in agreement with that of the reported natural nucleoside <bold>1</bold> [<xref ref-type="bibr" rid="B12-marinedrugs-10-00881">12</xref>].</p>
    </sec>
    <sec>
      <title>3. Experimental Section</title>
      <sec>
        <title>3.1. General</title>
        <p>4-Chloro-5-iodo-7<italic>H</italic>-pyrrolo[2,3-<italic>d</italic>]pyrimidine was synthesized in our lab on 500 g scale. BSA and TMSOTf were purchased from Sigma Aldrich. MeCN was dried over CaH<sub>2</sub> and distilled prior to use. Thin layer chromatography was performed using silica gel GF-254 plates (Qing-Dao Chemical Company, Qingdao, China) with detection by UV (254 nm), or charting with 10% sulfuric acid in ethanol. Column chromatography was performed on silica gel (200–300 mesh, purchased from Qing-Dao Chemical Company, Qingdao, China). NMR spectra were recorded on a Bruker AV400 spectrometer and chemical shifts (δ) are reported in ppm. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were calibrated with TMS as internal standard and coupling constants (<italic>J</italic>) are reported in Hz. The ESI-HRMS were obtained on a Bruker Dalton microTOFQ II spectrometer in positive ion mode.</p>
      </sec>
      <sec>
        <title>3.2. Synthesis of 1,2-<italic>O</italic>-Isopropylidene-α-<sc>D</sc>-xylofuranose <italic>6</italic></title>
        <p><sc>D</sc>-Xylose (20.0 g, 134 mmoL) was suspended in acetone (500 mL) containing concentrated H<sub>2</sub>SO<sub>4</sub> (20.0 mL, 98%). The mixture was stirred for 30 min at room temperature. Then a solution of Na<sub>2</sub>CO<sub>3</sub> (26.0 g, 246 mmol) in water (224 mL) was added carefully with cooling to 0 °C. After addition, the mixture was stirred for a further 3 h. Then, solid Na<sub>2</sub>CO<sub>3</sub> (14.0 g, 132 mmoL) was added in 3 portions over 30 min. The resulted Na<sub>2</sub>SO<sub>4</sub> was filtered off and washed with acetone. The combined filtrates were evaporated to give crude <bold>6</bold>, which was purified by a silica gel column (CHCl<sub>3</sub>:Me<sub>2</sub>CO = 18:1, R<sub>f</sub> = 0.32) to afford crystallized <bold>6</bold> (22.2 g, 87%). mp 42–43 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.97 (d, <italic>J</italic>= 4.4 Hz, 1H), 4.51 (d, <italic>J</italic> = 4.4 Hz, 1H), 4.31 (d, <italic>J</italic> = 2.0 Hz, 1H), 4.27 (d, <italic>J</italic> = 4.4 Hz, 1H), 4.16 (q, 1H), 4.09 (d, <italic>J</italic> = 4.8 Hz, 1H), 4.03 (d, <italic>J</italic>= 2.8 Hz, 1H), 2.04 (s, 1H), 1.47 (s, 3H), 1.31 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 111.8, 104.8, 85.6, 78.8, 78.7, 61.0, 26.7, 26.2.</p>
      </sec>
      <sec>
        <title>3.3. Synthesis of 5-<italic>O</italic>-Tosylate-1,2-<italic>O</italic>-isopropylidene-α-<sc>D</sc>-xylofuranose <italic>7</italic></title>
        <p>A solution of TsCl (83.9 g, 440 mmoL) in THF (500 mL) was added slowly to 1,2-<italic>O</italic>-isopropylidene-α-<sc>D</sc>-xylofuranose <bold>6</bold> (76.1 g, 400 mmol) in THF (400 mL) and Et<sub>3</sub>N (300 mL) at 0 °C. After addition, the solution was stirred at room temperature overnight. CH<sub>3</sub>OH (10 mL) was added to quench the reaction. After filtration, the resulting solution was evaporated to dryness. The residue was dissolved in EtOAc (500 mL) and washed with H<sub>2</sub>O (100 mL), sat. NaHCO<sub>3</sub> (100 mL) and brine (100 mL), then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration, the solution was evaporated under reduced pressure. The residue was purified over a silica gel column (EtOAc:Hexane = 1:1) to afford <bold>7</bold> (126.7 g, 92%). mp 134–135 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.80 (d, <italic>J</italic> = 8.4 Hz, 2H), 7.36 (d, <italic>J</italic> = 8.0 Hz, 2H), 5.88 (d, <italic>J</italic> = 4.8 Hz, 1H), 4.52 (d, <italic>J</italic> = 3.6 Hz, 1H), 4.34~4.31 (m, 3H), 4.13 (q, 1H), 2.46 (s, 3H), 2.27 (d, <italic>J </italic>= 4.8 Hz, 1H), 1.59 (s, 1H), 1.47 (s, 3H), 1.30 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 145.3, 132.4, 130.0, 128.0, 112.2, 104.9, 85.0, 76.7, 74.3, 66.0, 26.8, 26.2, 21.7; MS (ESI) <italic>m/z</italic> 345.2 [M + H]<sup>+</sup>.</p>
      </sec>
      <sec>
        <title>3.4. Synthesis of 5-Deoxy-1,2-<italic>O</italic>-isopropylidene-α-<sc>D</sc>-xylofuranose <italic>8</italic></title>
        <p>LiAlH<sub>4</sub> (3.8 g, 100 mmol) was added in portions to 5-<italic>O</italic>-tosylate-1,2-<italic>O</italic>-isopropylidene-α-<sc>D</sc>-xylofuranose <bold>7</bold> (68.9 g, 200 mmol) in anhydrous THF (800 mL). The resulting suspension was refluxed for 6 h. EtOAc (50 mL) was added slowly to quench the reaction. Then H<sub>2</sub>O (100 mL) was added and the suspension was stirred for 2 h at room temperature. After filtration over Celite, the filtrate was evaporated to remove THF. EtOAc (500 mL) was added. The solution was washed with H<sub>2</sub>O (100 mL), sat. NaHCO<sub>3</sub> (100 mL) and brine (100 mL), then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration, the solution was evaporated under reduced pressure. The residue was purified over a silica gel column (EtOAc:Hexane = 1:2, R<sub>f</sub> = 0.35) to afford <bold>8</bold> (33.0 g, 95%) as white solid. mp 81–83 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.83 (d, <italic>J</italic> = 3.6 Hz, 1H), 4.47 (d, <italic>J</italic> = 3.6 Hz, 1H), 4.25 (t, 1H), 3.93 (s, 1H), 2.78 (d, <italic>J</italic> = 4.0 Hz, 1H), 1.44 (s, 3H), 1.24 (d, <italic>J </italic>= 8.0 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 111.4, 104.3, 85.5, 76.2, 76.1, 26.5, 26.1, 12.8; MS (ESI) <italic>m/z</italic> 175.3 [M + H]<sup>+</sup>.</p>
      </sec>
      <sec>
        <title>3.5. Synthesis of 5-Deoxy-3-<italic>O</italic>-benzoyl-1,2-<italic>O</italic>-isopropylidene-α-<sc>D</sc>-xylofuranose <italic>9</italic></title>
        <p>Benzoyl chloride (8.71 g, 62 mmol) was added slowly to a solution of 5-deoxy-1,2-<italic>O</italic>-isopropylidene-α-<sc>D</sc>-xylofuranose <bold>8</bold> (9 g, 51.7 mmol) in anhydrous pyridine (100 mL) at 0 °C. The resulting solution was stirred for 2 h at room temperature. Ethanol (0.5 mL) was added to quench the reaction. It was evaporated under reduced pressure to dryness. The residue was dissolved in DCM (300 mL) and washed with H<sub>2</sub>O (50 mL), sat. NaHCO<sub>3</sub> (50 mL) and brine (50 mL), then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration, the resulting solution was evaporated under reduced pressure. The residue was purified over a silica gel column (EtOAc:Hexane = 1:3, R<sub>f</sub> = 0.3) to afford <bold>9</bold> (14.0 g, 98%) as white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.02 (d, <italic>J </italic>= 7.6 Hz, 2H), 7.57 (t, 1H), 7.41 (t, 2H), 5.95 (d, <italic>J</italic> = 3.6 Hz, 1H), 5.32 (d, <italic>J</italic> = 2.4 Hz, 1H), 4.64 (d, <italic>J</italic> = 3.6 Hz, 1H), 4.54~4.49 (m, 1H),1.52 (s, 3H), 1.29 (t, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 165.3, 133.3, 129.7, 129.4, 129.4, 128.5, 128.5, 111.6, 104.6, 83.9, 78.0, 76.9, 75.2, 26.6, 26.1, 13.3; MS (ESI) <italic>m/z</italic> 279.2 [M + H]<sup>+</sup>.</p>
      </sec>
      <sec>
        <title>3.6. Synthesis of 5-Deoxy-3-<italic>O</italic>-benzoyl-1,2-<italic>O</italic>-diacetate-<sc>D</sc>-xylofuranose <italic>3</italic></title>
        <p>5-Deoxy-3-<italic>O</italic>-benzoyl-1,2-<italic>O</italic>-isopropylidene-α-<sc>D</sc>-xylofuranose <bold>9</bold> (7.15 g, 25.7 mmol) was dissolved in AcOH (130 mL) and Ac<sub>2</sub>O (150 mL). Concentrated H<sub>2</sub>SO<sub>4</sub> (7.5 mL) was added dropwise. The solution was stirred at room temperature for 26 h. The solution was poured into H<sub>2</sub>O (500 mL) and extracted with DCM (3 × 100 mL). The combined organic layer was washed with H<sub>2</sub>O (3 × 50 mL), sat. NaHCO<sub>3</sub> (3 × 50 mL) and brine (50 mL), then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration, the resulting solution was evaporated under reduced pressure to afford <bold>10</bold> (6.5 g, 78%) as anomers. It was used directly without further purification. </p>
      </sec>
      <sec>
        <title>3.7. Vorbrüggen Glycosylation of 5′-Deoxy-1,2,3-<italic>tri</italic>-<italic>O</italic>-acetyl-β-<sc>D</sc>-xylofuranose 5 and 5-Iodo-7<italic>H</italic>-pyrrolo<italic>[</italic>2,3-<italic>d]</italic>pyrimidine <italic>10</italic></title>
        <p>To a suspension of 4-chloro-5-iodo-7<italic>H</italic>-pyrrolo[2,3-<italic>d</italic>]pyrimidine <bold>4</bold> (23.9 g, 85.5 mmoL) in dry MeCN (350 mL) was added BSA (20.9 g, 25 mL, 103 mmol) and stirred for 10 min at room temperature. After addition of 5-deoxy-3-<italic>O</italic>-benzoyl-1,2-<italic>O</italic>-diacetate-<sc>D</sc>-xylofuranose <bold>3</bold> (27.5 g, 85.5 mmol), TMSOTf (19.0 g, 15.5 mL, 85.5 mmol) was added to the mixture. The mixture was stirred for 15 min before heating to 80 °C for 12 h. The reaction was cooled to room temperature. Water (400 mL) was added to quench the reaction. The solution was extracted with EtOAc (300 mL × 3). The combined organic layer was washed with sat. NaHCO<sub>3</sub> (350 mL × 1) and brine (350 mL × 2), and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. The residue was purified over a silica gel column (CH<sub>2</sub>Cl<sub>2</sub>–EtOAc, 25:1) to afford <bold>10</bold> (26 g, 56%). mp 136–137 °C;<sup>1</sup>H NMR (400 MHz, DMSO): δ 8.61 (s, 1H), 8.01 (d, 2H, <italic>J</italic> = 8.4 Hz), 7.79 (s, 1H), 7.63 (t, 1H, <italic>J </italic>= 6.8 Hz), 7.55 (d, 2H, <italic>J</italic> = 7.6 Hz), 6.44 (s, 1H), 5.56 (s, 1H), 5.47 (s, 1H), 4.63 (m, 1H), 2.19 (s, 3H), 1.43 (d, 3H, <italic>J</italic> = 6.4 Hz). <sup>13</sup>C NMR (100 MHz, DMSO): δ 169.1, 165.0, 152.8, 151.2, 150.5, 133.9, 133.4, 132.0, 129.8, 129.0, 128.5, 117.4, 87.8, 81.3, 78.4, 76.8, 76.6, 52.8, 20.6, 14.6; MS (ESI) <italic>m/z</italic> 542.2 [M + H]<sup>+</sup>; HRMS (ESI) <italic>m/z</italic> calcd for [M + H]<sup>+</sup> C<sub>20</sub>H<sub>18</sub>IClN<sub>3</sub>O<sub>5</sub>: 541.9974, found: 541.9968.</p>
      </sec>
      <sec>
        <title>3.8. Synthesis of 4-Amino-7-(5′-deoxy-β-<sc>D</sc>-xylofuranosyl)-5-iodo-pyrrolo<italic>[</italic>2,3-<italic>d]</italic>pyrimidine <italic>1</italic></title>
        <p>A solution of <bold>10</bold> (18.2 g, 33.6 mmol) in methanolic ammonia (saturated with NH<sub>3</sub> at 0 °C for 2 h, 200 mL) was placed in an autoclave and stirred at 130 °C for 12 h. After cooling, the mixture was concentrated to dryness and the residue was purified over a silica gel column (CH<sub>2</sub>Cl<sub>2</sub>–CH<sub>3</sub>OH, 20:1) to afford <bold>1</bold> (10.3 g, 82%) as yellow powder. mp 190-191 °C; [α]<sup>25</sup><sub>D</sub> −68 (<italic>c</italic> 0.1, CH<sub>3</sub>OH); CD: λ<sub>ext</sub> 240 nm (∆ε −2.6) and λ<sub>ext</sub> 209 nm (∆ε −4.4);<sup>1</sup>H NMR (400 Hz, DMSO): δ 8.11 (s, 1H, H-2), 7.60 (s, 1H, H-6), 6.73 (brs, 2H, NH<sub>2</sub>), 5.96 (d, 1H, <italic>J </italic>= 1.8 Hz, H-1′), 5.82 (d, 1H, <italic>J</italic> = 3.6 Hz, OH-2′), 5.69 (d, 1H, <italic>J </italic>= 4.3 Hz, OH-3′), 4.21 (m, 1H, H-4′), 4.12 (dd, 1H, <italic>J </italic>= 1.8, 3.6 Hz, H-2′), 3.81(dd, 1H, <italic>J</italic> = 3.6, 4.3 Hz, H-3′), 1.21 (d, 3H, <italic>J </italic>= 6.6 Hz, H-5′); <sup>13</sup>C NMR (100 Hz, DMSO): δ 157.6 (C-4), 152.3 (C-2), 150.0 (C-8), 128.6 (C-6), 103.4 (C-9), 89.8 (C-1′), 82.4 (C-2′), 78.4 (C-4′), 77.0 (C-3′), 51.8 (C-5), 14.4 (C-5′); HRMS (ESI) <italic>m/z</italic> calcd for [M + H]<sup>+</sup> C<sub>11</sub>H<sub>14</sub>IN<sub>4</sub>O<sub>3</sub>: 377.0105, found: 377.0098.</p>
      </sec>
    </sec>
    <sec sec-type="conclusions">
      <title>4. Conclusions</title>
      <p>In conclusion, a practical and efficient approach for 10 g scale synthesis of marine nucleoside 4-amino-7-(5′-deoxy-β-<sc>D</sc>-xylofuranosyl)-5-iodo-pyrrolo[2,3-<italic>d</italic>]pyrimidine <bold>1</bold> was developed on the basis of Vorbrüggen glycosylation. It has the merits of cost efficiency, mild reaction conditions, and easy access to diversity-oriented derivatives. We are currently in the process of applying this approach to other 4-amino-7-(5′-deoxy-β-<sc>D</sc>-xylofuranosyl)-pyrrolo[2,3-<italic>d</italic>]pyrimidine derivatives and studying their biological activities, such as insecticides, which will be reported in due course. </p>
    </sec>

  </body>
  <back>
    <ack>
    <title>Acknowledgments</title>
      <p>We thank NSFC (No. 20962009, 21062006), NCET (11-1000), Education Department of Jiangxi Province (GJJ 11223) and Bureau of Science &amp; Technology of Nanchang City for financial support.</p>
      
    </ack>
    <fn-group><fn><p><italic>Sample Availability</italic>: Samples of the compound <bold>1</bold> are available from the authors.</p></fn></fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B1-marinedrugs-10-00881">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duvall</surname>
              <given-names>L.R.</given-names>
            </name>
          </person-group>
          <article-title>Tubercidin</article-title>
          <source>Cancer Chemother. Rep.</source>
          <year>1963</year>
          <volume>30</volume>
          <fpage>61</fpage>
          <lpage>62</lpage>
        <pub-id pub-id-type="pmid">14051507</pub-id></citation>
      </ref>
      <ref id="B2-marinedrugs-10-00881">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hayashi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Karnio</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Oono</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Townsend</surname>
              <given-names>L.B.</given-names>
            </name>
            <name>
              <surname>Nozaki</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Toyocamycin specifically inhibits auxin signaling mediated by SCF(TIR1) pathway</article-title>
          <source>Phytochemistry</source>
          <year>2009</year>
          <volume>70</volume>
          <fpage>190</fpage>
          <lpage>197</lpage>
        <pub-id pub-id-type="doi">10.1016/j.phytochem.2008.12.020</pub-id><pub-id pub-id-type="pmid">19171357</pub-id></citation>
      </ref>
      <ref id="B3-marinedrugs-10-00881">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stockwin</surname>
              <given-names>L.H.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>S.X.</given-names>
            </name>
            <name>
              <surname>Stotler</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hollingshead</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Newton</surname>
              <given-names>D.L.</given-names>
            </name>
          </person-group>
          <article-title>ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC</article-title>
          <source>BMC Cancer</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>63</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2407-9-63</pub-id><pub-id pub-id-type="pmid">19232100</pub-id></citation>
      </ref>
      <ref id="B4-marinedrugs-10-00881">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suzuki</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Tahara</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Okazaki</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Okabe</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>R.T.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Potentiation of cytotoxicity of 1-β-<sc>D</sc>-arabinofuranosylcytosine for K562 human-leukemic cells by cadeguomycin</article-title>
          <source>Cancer Res.</source>
          <year>1987</year>
          <volume>47</volume>
          <fpage>713</fpage>
          <lpage>717</lpage>
        <pub-id pub-id-type="pmid">3467840</pub-id></citation>
      </ref>
      <ref id="B5-marinedrugs-10-00881">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jimeno</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Faircloth</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Sousa-Faro</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Scheuer</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Rinehart</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>New marine derived anticancer therapeutics—A journey from the sea to clinical trials</article-title>
          <source>Mar. Drugs</source>
          <year>2004</year>
          <volume>2</volume>
          <fpage>14</fpage>
          <lpage>29</lpage>
        <pub-id pub-id-type="doi">10.3390/md201014</pub-id></citation>
      </ref>
      <ref id="B6-marinedrugs-10-00881">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seela</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>X.H.</given-names>
            </name>
            <name>
              <surname>Budow</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Advances in the synthesis of 7-deazapurine-pyrrolo[2,3-<italic>d</italic>]pyrimidine-2′-deoxyribonucleosides including <sc>D</sc>-and <sc>L</sc>-enantiomers, fluoro derivatives and 2′,3′-dideoxyribonucleosides</article-title>
          <source>Curr. Org. Chem.</source>
          <year>2007</year>
          <volume>11</volume>
          <fpage>427</fpage>
          <lpage>462</lpage>
        <pub-id pub-id-type="doi">10.2174/138527207780059286</pub-id></citation>
      </ref>
      <ref id="B7-marinedrugs-10-00881">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Knapp</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of complex nucleoside antibiotics</article-title>
          <source>Chem. Rev.</source>
          <year>1995</year>
          <volume>95</volume>
          <fpage>1859</fpage>
          <lpage>1876</lpage>
        <pub-id pub-id-type="doi">10.1021/cr00038a006</pub-id></citation>
      </ref>
      <ref id="B8-marinedrugs-10-00881">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Isono</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Nucleoside antibiotics-structure, biological-acitvity and biosynthesis</article-title>
          <source>J. Antibiot.</source>
          <year>1988</year>
          <volume>41</volume>
          <fpage>1711</fpage>
          <lpage>1739</lpage>
        <pub-id pub-id-type="doi">10.7164/antibiotics.41.1711</pub-id><pub-id pub-id-type="pmid">3061990</pub-id></citation>
      </ref>
      <ref id="B9-marinedrugs-10-00881">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Q.-L.</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>N.-Y.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>X.-P.</given-names>
            </name>
          </person-group>
          <article-title>Deoxyuridines from the marine sponge associated actinomycete streptomyces microflavus</article-title>
          <source>Mar. Drugs</source>
          <year>2011</year>
          <volume>9</volume>
          <fpage>690</fpage>
          <lpage>695</lpage>
        <pub-id pub-id-type="doi">10.3390/md9050690</pub-id><pub-id pub-id-type="pmid">21673882</pub-id></citation>
      </ref>
      <ref id="B10-marinedrugs-10-00881">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sagar</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kaur</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Minneman</surname>
              <given-names>K.P.</given-names>
            </name>
          </person-group>
          <article-title>Antiviral lead compounds from marine sponges</article-title>
          <source>Mar. Drugs</source>
          <year>2010</year>
          <volume>8</volume>
          <fpage>2619</fpage>
          <lpage>2638</lpage>
        <pub-id pub-id-type="doi">10.3390/md8102619</pub-id><pub-id pub-id-type="pmid">21116410</pub-id></citation>
      </ref>
      <ref id="B11-marinedrugs-10-00881">
        <label>11.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Bhakuni</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Rawat</surname>
              <given-names>D.S.</given-names>
            </name>
          </person-group>
          <source>Bioactive Marine Natural Products</source>
          <publisher-name>Co-published by Springer with Anamaya Publishers</publisher-name>
          <publisher-loc>New Delhi, India</publisher-loc>
          <year>2005</year>
          <fpage>208</fpage>
          <lpage>234</lpage>
        </citation>
      </ref>
      <ref id="B12-marinedrugs-10-00881">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Margiastuti</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Ogi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Teruya</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Taira</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Suenaga</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ueda</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>An unusual iodinated 5′-deoxyxylofuranosyl nucleoside from an <italic>Okinawan ascidian</italic>, <italic>Diplosoma</italic> sp.</article-title>
          <source>Chem. Lett.</source>
          <year>2008</year>
          <volume>37</volume>
          <fpage>448</fpage>
          <lpage>449</lpage>
        <pub-id pub-id-type="doi">10.1246/cl.2008.448</pub-id></citation>
      </ref>
      <ref id="B13-marinedrugs-10-00881">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vorbruggen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Krolikiewicz</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Bennua</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Nucleoside synthesis. 22. Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysis</article-title>
          <source>Chem. Ber. Recl.</source>
          <year>1981</year>
          <volume>114</volume>
          <fpage>1234</fpage>
          <lpage>1255</lpage>
          <pub-id pub-id-type="doi">10.1002/cber.19811140404</pub-id>
        </citation>
      </ref>
      <ref id="B14-marinedrugs-10-00881">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niedballa</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Vorbruggen</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>General synthesis of <italic>N</italic>-glycosides. 6. Mechanism of stannic chloride catalyzed silyl Hibert–Johnson reaction</article-title>
          <source>J. Org. Chem.</source>
          <year>1976</year>
          <volume>41</volume>
          <fpage>2084</fpage>
          <lpage>2086</lpage>
          <pub-id pub-id-type="doi">10.1021/jo00874a002</pub-id>
        </citation>
      </ref>
      <ref id="B15-marinedrugs-10-00881">
        <label>15.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Vorbrüggen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Ruh-Pohlenz</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <source>Handbook of Nucleoside Synthesis</source>
          <publisher-name>John Wiley Sons</publisher-name>
          <publisher-loc>New York, NY, USA</publisher-loc>
          <year>2001</year>
        </citation>
      </ref>
      <ref id="B16-marinedrugs-10-00881">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bio</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Waters</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Savary</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Cowden</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Buck</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>Z.G.J.</given-names>
            </name>
            <name>
              <surname>Tschaen</surname>
              <given-names>D.M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Practical synthesis of a potent hepatitis C virus RNA replication inhibitor</article-title>
          <source>J. Org. Chem.</source>
          <year>2004</year>
          <volume>69</volume>
          <fpage>6257</fpage>
          <lpage>6266</lpage>
        <pub-id pub-id-type="doi">10.1021/jo0491096</pub-id><pub-id pub-id-type="pmid">15357584</pub-id></citation>
      </ref>
      <ref id="B17-marinedrugs-10-00881">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dempcy</surname>
              <given-names>R.O.</given-names>
            </name>
            <name>
              <surname>Skibo</surname>
              <given-names>E.B.</given-names>
            </name>
          </person-group>
          <article-title>Regioselective synthesis of imidazo [4,5-<italic>g</italic>]quinazoline quinone nucleosides and quinazoline amino nucleosides. Studies of their xanthine-oxidase and purine nucleoside phosphorylase substrate activity</article-title>
          <source>J. Org. Chem.</source>
          <year>1991</year>
          <volume>56</volume>
          <fpage>776</fpage>
          <lpage>785</lpage>
          <pub-id pub-id-type="doi">10.1021/jo00002a052</pub-id>
        </citation>
      </ref>
      <ref id="B18-marinedrugs-10-00881">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramasamy</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Robins</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Revankar</surname>
              <given-names>G.R.</given-names>
            </name>
          </person-group>
          <article-title>A facile synthesis of tubercidin and related 7-deazapurine nucleosides via the stereospecific sodium-salt glycosylation procedure</article-title>
          <source>Tetrahedron Lett.</source>
          <year>1987</year>
          <volume>28</volume>
          <fpage>5107</fpage>
          <lpage>5110</lpage>
        <pub-id pub-id-type="doi">10.1016/S0040-4039(00)95603-X</pub-id></citation>
      </ref>
      <ref id="B19-marinedrugs-10-00881">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kazimierczuk</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Revankar</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Robins</surname>
              <given-names>R.K.</given-names>
            </name>
          </person-group>
          <article-title>Total synthesis of certain 2-monosubstituted-tubercidin, 6-mono-substituted-tubercidin and 2,6-disubstituted-tubercidin derivatives-synthesis of tubercidin via the sodium-salt glycosylation procedure</article-title>
          <source>Nucleic Acids Res.</source>
          <year>1984</year>
          <volume>12</volume>
          <fpage>1179</fpage>
          <lpage>1192</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/12.2.1179</pub-id><pub-id pub-id-type="pmid">6694909</pub-id></citation>
      </ref>
      <ref id="B20-marinedrugs-10-00881">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seela</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Westermann</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Bindig</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Liquid–liquid and solid–liquid phase-transfer glycosylation of pyrrolo[2,3-<italic>d</italic>]pyrimidines-stereospecific synthesis of 2-deoxy-β-<sc>D</sc>-ribofuranosides related to 2′-deoxy-7-carbaguanosine</article-title>
          <source>J. Chem. Soc. Perkin Trans. 1</source>
          <year>1988</year>
          <fpage>697</fpage>
          <lpage>702</lpage>
        </citation>
      </ref>
      <ref id="B21-marinedrugs-10-00881">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seela</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Muth</surname>
              <given-names>H.P.</given-names>
            </name>
            <name>
              <surname>Bindig</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of 6-substituted 7-carbapurine 2′,3′-dideoxynucleosides-solid-liquid phase-transfer glycosylation of 4-chloropyrrolo[2,3-<italic>d</italic>]pyrimidine and deoxygenation of its 2′-deoxyribofuranoside</article-title>
          <source>Synthesis</source>
          <year>1988</year>
          <fpage>670</fpage>
          <lpage>674</lpage>
        </citation>
      </ref>
      <ref id="B22-marinedrugs-10-00881">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lupke</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Seela</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Ribosidation of 7<italic>H</italic>-pyrrolo[2,3-<italic>d</italic>] pyrimidin-4(3<italic>H</italic>)-one at N-3</article-title>
          <source>Chem. Ber. Recl.</source>
          <year>1979</year>
          <volume>112</volume>
          <fpage>3526</fpage>
          <lpage>3529</lpage>
        <pub-id pub-id-type="doi">10.1002/cber.19791121021</pub-id></citation>
      </ref>
      <ref id="B23-marinedrugs-10-00881">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilcox</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Otoski</surname>
              <given-names>R.M.</given-names>
            </name>
          </person-group>
          <article-title>Stereoselective preparations of ribofuranosyl chlorides and ribofuranosyl acetates-solvent effects and stereoselectivity in the reaction of ribofuranosyl acetates with trimethylallylsilane</article-title>
          <source>Tetrahedron Lett.</source>
          <year>1986</year>
          <volume>27</volume>
          <fpage>1011</fpage>
          <lpage>1014</lpage>
        <pub-id pub-id-type="doi">10.1016/S0040-4039(86)80035-1</pub-id></citation>
      </ref>
      <ref id="B24-marinedrugs-10-00881">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kane</surname>
              <given-names>P.D.</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>The preparation and utility of ethyl 2-(5′-<italic>O</italic>-tertbutyldimethylsilyl-2′,3′-<italic>O</italic>-isopropylidene-β-<sc>D</sc>-ribofuranosyl)propenoate as a key intermediate for C-nucleoside synthesis</article-title>
          <source>J. Chem. Soc. Perkin Trans. 1</source>
          <year>1984</year>
          <fpage>657</fpage>
          <lpage>660</lpage>
        </citation>
      </ref>
      <ref id="B25-marinedrugs-10-00881">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>H.X.</given-names>
            </name>
            <name>
              <surname>Dou</surname>
              <given-names>Y.H.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Ju</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Efficient and practical synthesis of 5′-deoxytubercidin and its analogues via vorbruggen glycosylation</article-title>
          <source>Synthesis</source>
          <year>2011</year>
          <fpage>1442</fpage>
          <lpage>1446</lpage>
        </citation>
      </ref>
      <ref id="B26-marinedrugs-10-00881">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seela</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Ming</surname>
              <given-names>X.</given-names>
            </name>
          </person-group>
          <article-title>7-Functionalized 7-deazapurine β-<sc>D</sc>- and β-<sc>L</sc>-ribonucleosides related to tubercidin and 7-deazainosine: glycosylation of pyrrolo 2,3-d pyrimidines with 1-<italic>O</italic>-acetyl-2,3,5-tri-<italic>O</italic>-benzoyl-β-<sc>D</sc> or β-<sc>L</sc>-ribofuranose</article-title>
          <source>Tetrahedron</source>
          <year>2007</year>
          <volume>63</volume>
          <fpage>9850</fpage>
          <lpage>9861</lpage>
        <pub-id pub-id-type="doi">10.1016/j.tet.2007.06.107</pub-id></citation>
      </ref>
      <ref id="B27-marinedrugs-10-00881">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seela</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>X.H.</given-names>
            </name>
          </person-group>
          <article-title>Pyrrolo[2,3-<italic>d</italic>]pyrimidine β-<sc>L</sc>-nucleosides containing 7-deazaadenine, 2-amino-7-deazaadenine, 7-deazaguanine, 7-deazaisoguanine, and 7-deazaxanthine</article-title>
          <source>Collect. Czech. Chem. Commun.</source>
          <year>2006</year>
          <volume>71</volume>
          <fpage>956</fpage>
          <lpage>977</lpage>
        <pub-id pub-id-type="doi">10.1135/cccc20060956</pub-id></citation>
      </ref>
      <ref id="B28-marinedrugs-10-00881">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seela</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>X.H.</given-names>
            </name>
          </person-group>
          <article-title>7-Functionalized 7-deazapurine ribonucleosides related to 2-aminoadenosine, guanosine, and xanthosine: Glycosylation of pyrrolo 2,3-d pyrimidines with 1-<italic>O</italic>-acetyl-2,3,5-tri-<italic>O</italic>-benzoyl-<sc>D</sc>-ribofuranose</article-title>
          <source>J. Org. Chem.</source>
          <year>2006</year>
          <volume>71</volume>
          <fpage>81</fpage>
          <lpage>90</lpage>
        <pub-id pub-id-type="doi">10.1021/jo0516640</pub-id><pub-id pub-id-type="pmid">16388621</pub-id></citation>
      </ref>
      <ref id="B29-marinedrugs-10-00881">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moravcova</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Capkova</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stanek</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>One-pot synthesis of 1,2-<italic>O</italic>-isopropylidene-α-<sc>D</sc>-xylofuranose</article-title>
          <source>Carbohydr. Res.</source>
          <year>1994</year>
          <volume>263</volume>
          <fpage>61</fpage>
          <lpage>66</lpage>
        <pub-id pub-id-type="doi">10.1016/0008-6215(94)00165-0</pub-id></citation>
      </ref>
      <ref id="B30-marinedrugs-10-00881">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hildebrandt</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Practical synthesis of optically pure 3,4-epoxy-5-methyldihydro-2(3<italic>H</italic>)-furanones from <sc>D</sc>-xylose by regioselective and stereoselective functionalization</article-title>
          <source>Carbohydr. Res.</source>
          <year>1991</year>
          <volume>214</volume>
          <fpage>87</fpage>
          <lpage>93</lpage>
        <pub-id pub-id-type="doi">10.1016/S0008-6215(00)90532-9</pub-id></citation>
      </ref>
      <ref id="B31-marinedrugs-10-00881">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mathe</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Imbach</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Gosselin</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>1,2-Di-<italic>O</italic>-acetyl-5-<italic>O</italic>-benzoyl-3-deoxy-<sc>L</sc>-erythro-pentofuran ose, a convenient precursor for the stereospecific synthesis of nucleoside analogues with the unnatural β-<sc>L</sc>-configuration</article-title>
          <source>Carbohydr. Res.</source>
          <year>2000</year>
          <volume>323</volume>
          <fpage>226</fpage>
          <lpage>229</lpage>
        <pub-id pub-id-type="pmid">10782306</pub-id></citation>
      </ref>
      <ref id="B32-marinedrugs-10-00881">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reigan</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gbaj</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Stratford</surname>
              <given-names>I.J.</given-names>
            </name>
            <name>
              <surname>Bryce</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2008</year>
          <volume>43</volume>
          <fpage>1248</fpage>
          <lpage>1260</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ejmech.2007.07.015</pub-id><pub-id pub-id-type="pmid">17870212</pub-id></citation>
      </ref>
      <ref id="B33-marinedrugs-10-00881">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reigan</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gbaj</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Chinje</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Stratford</surname>
              <given-names>I.J.</given-names>
            </name>
            <name>
              <surname>Douglas</surname>
              <given-names>K.T.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase</article-title>
          <source>Biorg. Med. Chem. Lett.</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>5247</fpage>
          <lpage>5250</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmcl.2004.08.036</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
